Poongjeon Pharmacy

풍전약품 · 298060

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$17.6M (₩24.3B)

Overview

Poongjeon Pharmacy is a Korean company listed on KOSDAQ that operates across three business lines: developing stem-cell therapies for rare diseases, making and distributing hair-care and skin-care cosmetics under its Iroro and Dermassimo brands, and wholesaling prescription medicines to large hospitals.

Its cosmetics reach consumers through its own online stores, home-shopping channels, and export partners in Malaysia and Japan. The business is structured around three distinct divisions, with the pharmaceutical wholesale arm added through a merger.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$17.3M

▲ +2790.3% YoY

Operating profit · FY2025

−US$3.3M

Loss narrowed

Net income · FY2025

US$146.7K

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$504.1K(₩695.7M)	US$597.7K(₩824.8M)	US$17.3M(₩23.8B)
Operating profit	−US$9.4M(−₩13B)	−US$8.2M(−₩11.3B)	−US$3.3M(−₩4.5B)
Net income	−US$17.4M(−₩24B)	−US$9M(−₩12.4B)	US$146.7K(₩202.5M)

Revenue

FY2023US$504.1K
FY2024US$597.7K
FY2025US$17.3M

Operating profit

FY2023−US$9.4M
FY2024−US$8.2M
FY2025−US$3.3M

Net income

FY2023−US$17.4M
FY2024−US$9M
FY2025US$146.7K

Key ratios (FY2025)

ROE

0.6%

Debt/Eq

44.1%

Op. margin

-19.0%

Net margin

0.8%

Rev. YoY

▲ +2790.3%

Why it matters

The company absorbed Dermassimo brand owner (주)더마시모 by merger and has a further planned merger with pharmaceutical wholesaler 풍전약품(주) to add the medicines distribution division.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?